PRTK News and Press, Paratek Pharmaceuticals Inc. From 01/06/21

BOSTON, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, gov...

Paratek Pharmaceuticals (PRTK) says it has entered into a $60M non-recourse loan agreement with an affiliate of R-Bridge Healthcare Investment Advisory for 12 years; The proceeds will be used for repayment of Hercules senior secured debt.Paratek says this non-recourse loan will be repaid...

BOSTON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, gov...

Nuzyra launch trajectory is top of class compared with other antibiotics. BARDA deal signed late 2019 is worth $285M. If things go even slightly right for the company, it could easily be a 5-bagger in a few years. No dilution in sight which is refreshing for a biotech. F...

BOSTON, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, gov...

The following slide deck was published by Paratek Pharmaceuticals, Inc. in conjunction with their 2020 Q3 earnings call. For further details see: Paratek Pharmaceuticals, Inc. 2020 Q3 - Results - Earnings Call Presentation

Paratek Pharmaceuticals, Inc. (PRTK) Q3 2020 Earnings Conference Call November 05, 2020, 16:30 ET Company Participants Ben Strain - VP, IR Evan Loh - CEO & Director Adam Woodrow - President & Chief Commercial Officer Randall Brenner - Chief Development & Regulatory Officer Confere...

Paratek Pharmaceuticals (PRTK): Q3 GAAP EPS of -$0.46 beats by $0.15.Revenue of $13.66M (+247.6% Y/Y) beats by $1.76M.Company now anticipates FY20 20 total revenue to be at the higher end of the previously communicated range of $78M  to  $83M driven by strong NUZYRA net rev...

-- N UZYRA® (omadacycline) Generated Net Product Revenue of $10.9 Million in the T hird Q uarter 2020; a 35% I ncrease O ver the P rior Q uarter -- Paratek now A nticipates F ull Y ear&#x...

BOSTON, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, go...